Abstract
Objectives: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP). Methods: We examined 491 patients with systolic CHF (age: 63±11 years, 91%men, New York Heart Association [NYHA] class [I/ II/III/IV]: 9%/45%/38%/8%, 69% ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. Results: Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p
| Original language | English |
|---|---|
| Article number | e14506 |
| Journal | PLoS One |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2011 |
Fingerprint
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. / Jankowska, Ewa A.; Filippatos, Gerasimos S.; von Haehling, Stephan; Papassotiriou, Jana; Morgenthaler, Nils G.; Cicoira, Mariantonietta; Schefold, Joerg C.; Rozentryt, Piotr; Ponikowska, Beata; Doehner, Wolfram; Banasiak, Waldemar; Hartmann, Oliver; Struck, Joachim; Bergmann, Andreas; Anker, Stefan D.; Ponikowski, Piotr.
In: PLoS One, Vol. 6, No. 1, e14506, 2011.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1
AU - Jankowska, Ewa A.
AU - Filippatos, Gerasimos S.
AU - von Haehling, Stephan
AU - Papassotiriou, Jana
AU - Morgenthaler, Nils G.
AU - Cicoira, Mariantonietta
AU - Schefold, Joerg C.
AU - Rozentryt, Piotr
AU - Ponikowska, Beata
AU - Doehner, Wolfram
AU - Banasiak, Waldemar
AU - Hartmann, Oliver
AU - Struck, Joachim
AU - Bergmann, Andreas
AU - Anker, Stefan D.
AU - Ponikowski, Piotr
PY - 2011
Y1 - 2011
N2 - Objectives: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP). Methods: We examined 491 patients with systolic CHF (age: 63±11 years, 91%men, New York Heart Association [NYHA] class [I/ II/III/IV]: 9%/45%/38%/8%, 69% ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. Results: Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p
AB - Objectives: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP). Methods: We examined 491 patients with systolic CHF (age: 63±11 years, 91%men, New York Heart Association [NYHA] class [I/ II/III/IV]: 9%/45%/38%/8%, 69% ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. Results: Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p
UR - http://www.scopus.com/inward/record.url?scp=79251581599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79251581599&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0014506
DO - 10.1371/journal.pone.0014506
M3 - Article
VL - 6
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 1
M1 - e14506
ER -